Annals of Oncology Advance Access originally published online on February 23, 2006
Annals of Oncology 2006 17(4):652-656; doi:10.1093/annonc/mdl005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group
1 Mayo Clinic and Mayo Foundation, Rochester, MN; 2 Michigan Cancer Consortium, Ann Arbor, MI; 3 Sioux Valley Clinic Oncology, Sioux Falls, SD; 4 Wichita Community Clinical Oncology Program, Wichita, KS; 5 Missouri Valley Cancer Consortium, Omaha, NE; 6 Metro-Minnesota Community Oncology Program, St. Louis Park, MN; 7 Duluth CCOP, Duluth, MN, USA
* Correspondence to: Dr A. Jatoi, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Tel: +1-507-538-0548; Fax: +1-507-284-1803; E-mail: Jatoi.aminah{at}mayo.edu
Background: Previous studies suggest that the combination of docetaxel and capecitabine are worthy of further testing in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. We therefore undertook this phase II study to test this combination in a multi-institutional, first-line clinical trial.
Patients and methods: Forty-four eligible patients with histologic or cytologic confirmation of the above malignancy were recruited. The cohort had Eastern Cooperative Oncology Group performance scores of 0, 1 and 2 in 59%, 39% and 2% of patients, respectively. Median age was 57 years (range 32–77 years). Adequate organ function was a requirement for study entry. All patients were prescribed docetaxel 75 mg/m2 intravenously on day 1 and capecitabine 825 mg/m2 orally twice a day on days 1–14 of a 21-day cycle.
Results: The tumor response rate was 39% [95% confidence interval (CI) 23% to 55%]. There were two complete responses and the rest were partial. Median survival was 9.4 months (95% CI 6.3–10.7 months) and median time-to-tumor progression was 4.2 months (95% CI 3.6–5.6 months). There was one treatment-related death from a myocardial infarction and dysrhythmia. Commonly occurring grade 3 adverse events included neutropenia (11 patients), infection (five patients), constipation (three patients), thrombosis (three patients), dyspnea (three patients) and hand–foot syndrome (three patients). In addition, 24/45 patients developed grade 4 neutropenia.
Conclusions: The regimen docetaxel and capecitabine shows activity in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. This regimen merits further study.
Key words: capecitabine, chemotherapy, docetaxel, gastric cancer, gastroesophageal junction, stomach
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Starling, S. Rao, D. Cunningham, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, and A. R. Norman Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group J. Clin. Oncol., August 10, 2009; 27(23): 3786 - 3793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Enzinger, D. P. Ryan, J. W. Clark, A. Muzikansky, C. C. Earle, M. H. Kulke, J. A. Meyerhardt, L. S. Blaszkowsky, A. X. Zhu, P. Fidias, et al. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer Ann. Onc., March 1, 2009; 20(3): 475 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Orditura, E Martinelli, G Galizia, C Carlomagno, G Aurilio, L Vecchione, E. Lieto, S De Placido, G Catalano, F Ciardiello, et al. Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study Ann. Onc., October 1, 2006; 17(10): 1529 - 1532. [Abstract] [Full Text] [PDF]
|
|